Early growth response-1: Key mediators of cell death and novel targets for cardiovascular disease therapy

Front Cardiovasc Med. 2023 Mar 28:10:1162662. doi: 10.3389/fcvm.2023.1162662. eCollection 2023.

Abstract

Significance: Cardiovascular diseases are seen to be a primary cause of death, and their prevalence has significantly increased across the globe in the past few years. Several studies have shown that cell death is closely linked to the pathogenesis of cardiovascular diseases. Furthermore, many molecular and cellular mechanisms are involved in the pathogenesis of the cardiac cell death mechanism. One of the factors that played a vital role in the pathogenesis of cardiac cell death mechanisms included the early growth response-1 (Egr-1) factor.

Recent advances: Studies have shown that abnormal Egr-1 expression is linked to different animal and human disorders like heart failure and myocardial infarction. The biosynthesis of Egr-1 regulates its activity. Egr-1 can be triggered by many factors such as serum, cytokines, hormones, growth factors, endotoxins, mechanical injury, hypoxia, and shear stress. It also displays a pro-apoptotic effect on cardiac cells, under varying stress conditions. EGR1 mediates a broad range of biological responses to oxidative stress and cell death by combining the acute changes occurring in the cellular environment with sustained changes in gene expression.

Future directions: The primary regulatory role played by the Egr-1-targeting DNAzymes, microRNAs, and oligonucleotide decoy strategies in cardiovascular diseases were identified to provide a reference to identify novel therapeutic targets for cardiovascular diseases.

Keywords: apoptosis; autophagy; cardiovascular diseases; cell death; early growth response-1; transcription factors.

Publication types

  • Review

Grants and funding

This work was supported by the National Natural Science Foundation of China (82060080), Gansu science and Technology Department Project (20YF3WA016, 21JR11RA116), Project of Lanzhou Science and Technology Bureau (2019-RC36) and Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (CY2022-MS-A06 and CY2022-QN-A17). This study was also supported by the Gansu heart rehabilitation engineering research center (CRQI-C00535) and Medical Postgraduate Training Innovation Development Project (lzuyxcx-2022-128).